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Beyond medical therapy, different interventional and surgical approaches exist for treatment
of pulmonary arterial hypertension (PAH). Atrial septostomy has been applied in patients
with lack of response to medical therapy in the absence of other surgical treatment options.
With growing experience, procedure-related death rates have been reduced to 5.4%, and the
most suitable patient group has been identified among patients with a mean right atrial
pressure between 10 and 20 mm Hg. Pulmonary endarterectomy is the accepted form of
treatment for patients with chronic thromboembolic pulmonary hypertension. Establishing
the diagnosis and the classification of the type of lesions by pulmonary angiography is crucial
for optimal patient selection. Perioperative mortality rates have been reduced to 10% in
experienced centers, and the hemodynamic improvement is dramatic and sustained. Lung and
heart-lung transplantation remains the procedure of choice for patients unsuitable for other
treatment modalities. Timing of the procedure is difficult because waiting times vary between
centers and usually are in a high range. Early referral of patients unresponsive to other
treatment forms is therefore of importance to avoid transplantation of patients with
established significant comorbidity. The survival rate during the first five years after
transplantation for PAH is intermediate among the lung diseases, lower than chronic
obstructive pulmonary disease but higher than idiopathic pulmonary fibrosis. (J Am Coll
Cardiol 2004;43:73S–80S) © 2004 by the American College of Cardiology FoundationG
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mifferent interventional and surgical approaches for treat-
ent of pulmonary arterial hypertension (PAH) have been
eveloped in the last two decades. We review here the three
ajor components: atrial septostomy, pulmonary endarter-
ctomy, and lung transplantation.
TRIAL SEPTOSTOMY
he use of atrial septostomy (AS) in PAH is supported by
he fact that deterioration in symptoms and death in PAH
re associated with right ventricular failure (RVF). An AS
n this setting creates a right-to-left shunt that increases
ardiac output and, despite the fall in systemic arterial
xygen saturation, augments systemic oxygen transport
SOT). In addition, the shunt decompresses the heart and
meliorates RVF.
Blade balloon atrial septostomy (BBAS) as a palliative
herapy for refractory PAH was first reported in 1983 (1,2).
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ung Research, Freeman Hospital, Cambridge, United Kingdom.rManuscript received November 26, 2003; accepted February 3, 2004.raded balloon-dilation AS (BDAS), a variant of BBAS, is
he technique most used in recent series (3,4), and it has
roduced results similar to those of BBAS in terms of
ymptomatic and hemodynamic benefits but with an appar-
nt reduction in the procedure-related risks. Procedures
hould be performed only in centers experienced in both
nterventional cardiology and PAH (5,6).
The precise role of AS in the treatment of PAH remains
ncertain because most of the knowledge regarding its use
omes from small series or case reports. The potential benefi-
ial effects and risks of AS were addressed in a review derived
rom an analysis of 64 cases from the published reports (5).
his knowledge has now expanded with the report of another
6 cases in the last few years (3,7,8). Severe idiopathic PAH
as been the main indication for AS. Other indications have
ncluded PAH associated with surgically corrected congenital
eart disease, peripheral chronic thromboembolic pulmonary
ypertension (CTEPH) (5), and, more recently, PAH associ-
ted with systemic sclerosis (8). Most patients who have
ndergone AS had not responded to conventional treatment
5), had failed long-term prostacyclin therapy (3,9), or were
reated with the intention of bridging to lung transplantation
3,9).
In most reports the patients have been considered termi-
ally ill. Accordingly, there is an inherent risk of complica-
ions and death during the procedure. In the prior world-
ide experience (5), there was an overall procedure-related
ortality of 16%, and by univariate analysis, a baseline meanight atrial pressure (mRAP) 20 mm Hg was the variable
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Surgical Therapy of PAH June 16, 2004:73S–80Sost significantly associated with peri-procedural death.
owever, ever since recommendations to minimize this risk
ave been established (5), procedure-related mortality ap-
ears to be decreasing. In 74 recently reported BDAS
rocedures (3,4,9), there were only 4 immediate procedure-
elated deaths (5.4%). The improvement in hemodynamic
arameters at rest (i.e., an increase in cardiac index and
OT) is not the same for all patients and appears to depend
n the level of mRAP. Patients with a baseline mRAP
etween 10 to 20 mm Hg seem to have a better risk/benefit
atio (5,6). Little information exists with regard to the
ong-term hemodynamic effects of AS, and in only one
tudy (5) did it demonstrate an improvement in right
entricular function over time (7 to 27 months).
In most reports, symptoms and signs of RVF are im-
roved immediately after AS (i.e., syncope and/or signs of
ystemic venous congestion either disappear or decrease in
ntensity) (5). Likewise, exercise endurance, as assessed by
he 6-min walk test, was also improved in most of the
atients after AS (4). Although not completely elucidated,
echanisms such as a decompression effect on the heart
i.e., reduction of afterload) and an increase in SOT seem to
e responsible for the hemodynamic and beneficial clinical
ffects (6).
The impact of AS on long-term survival of patients with
AH has not been established in prospective and controlled
tudies. Most reported series, however, have suggested a
eneficial effect. In one report (3), long-term clinical out-
ome was dependent on the immediate hemodynamic
esponse to the procedure. In the worldwide experience (5),
edian survival was 19.5 months (range, 2 to 96 months),
nd late deaths primarily resulted from progression of the
ulmonary vascular disease (5).
Presently, the use of AS in the management of PAH is
ustified because of the disparate availability of treatments
hroughout the world, especially the limited access to lung
ransplantation. Current indications for AS, therefore, in-
lude failure of medical therapy (including oral calcium
hannel blocker, prostacyclin, or bosentan) with persisting
Abbreviations and Acronyms
AS  atrial septostomy
BBAS  blade balloon atrial septostomy
BDAS  balloon dilation atrial septostomy
CTEPH  chronic thromboembolic pulmonary
hypertension
mRAP  mean right atrial pressure
NYHA  New York Heart Association
PA  pulmonary artery
PAH  pulmonary arterial hypertension
PEA  pulmonary endarterectomy
PPH  primary pulmonary hypertension
PTE  pulmonary thromboendarterectomy
PVR  pulmonary vascular resistance
RVF  right ventricular failure
SOT  systemic oxygen transportnVF and/or recurrent syncope, bridging to transplantation
nd the absence of other therapeutic options (10).
To address some of the unanswered questions prospec-
ively (timing of procedure, combination with other thera-
ies, and so forth) regarding the precise role of AS, an
nternational Registry on the use of AS in PAH is under-
ay.
ULMONARY ENDARTERECTOMY
hronic thromboembolic pulmonary hypertension is an
nderdiagnosed consequence of unresolved acute pulmonary
mbolism with an incidence that is higher than generally
ppreciated (11). It is characterized by intraluminal throm-
us organization and fibrous stenoses or complete obstruc-
ions of the pulmonary artery (PA) branches, causing a
ersistent elevation of PA pressure, pulmonary vascular
esistance (PVR), and progressive right heart failure (11,12).
he prognosis of patients with thromboembolic pulmonary
ypertension is poor, and the survival rate is inversely
roportional to the degree of PAH (13). As in patients with
cute pulmonary embolism, the diagnosis is often missed or
elayed because the main symptoms (e.g., dyspnea) are
onspecific. Additionally, there is a general lack of aware-
ess of this disease and the chance of surgical cure.
Adequate preoperative patient evaluation and selection,
urgical technique and experience, meticulous postoperative
anagement, and a multidisciplinary approach are the basic
rerequisites for pulmonary endarterectomy (PEA).
iagnostic investigations. When PAH is clinically sus-
ected to be the cause of exertional dyspnea, right heart
ysfunction can be detected by transthoracic echocardiog-
aphy, whereas left heart conditions leading to PAH can be
xcluded. Pulmonary perfusion scanning allows differentia-
ion between thromboembolic and primary pulmonary per-
usion defects (12). High-resolution computed tomography
sing maximal intensity projections shows the distribution
f typical obstructive PA lesions at the main, lobar, and
egmental levels and a mosaic pattern of lung attenuation
ue to regional perfusion differences.
Pulmonary angiography remains the gold standard for the
iagnosis and preoperative evaluation of patients with
hromboembolic pulmonary hypertension. Biplane plate
lm or digital substraction angiography shows the exact
ocalization and the type of PA obstructions (11). Specific
xperience is required for the interpretation of angiograms
f CTEPH patients: irregularities of the vascular wall,
ntraluminal filling defects, stenoses or occlusion of central,
obar, segmental, and peripheral arteries caused by throm-
otic masses or fibrous webs and bands are characteristic
ngiographic features in CTEPH (Fig. 1).
Pulmonary fiberoptic angioscopy can be used to define
perability in selected patients with unclear angiographic
ndings or disproportionately severe PAH with mild an-
iographic obstructions. With increasing experience, mag-
etic resonance imaging using high-field technology and
f
i
a
p
o
P
l
d
t
A
a
g
l
[
m
d
m
e
t
l
i
W
P
m
t
n
P
c
t
3
a
s
e
D
b
t
a
o
t
e
C
t
f
c
e
t
s
s
l
p
c
t
r
t
r
c
a
r
o
r
t
s
p
P
p
P
c
m
f
a
p
u
t
d
v
p
m
F
r
t
75SJACC Vol. 43, No. 12 Suppl S Klepetko et al.
June 16, 2004:73S–80S Surgical Therapy of PAHast imaging techniques is becoming a helpful noninvasive
nvestigation in CTEPH patients because the lumen as well
s the organized tissue in the wall of the PA branches can be
recisely depicted in combination with an exact evaluation
f right heart function.
atient selection. Once the diagnosis of CTEPH is estab-
ished, the decision for surgical therapy is made based on the
egree of functional impairment, the severity of PAH, and
he surgical accessibility of the thromboembolic lesions (14).
preoperative period of at least three months of adequate
nticoagulation is mandatory. Patients considered for sur-
ery are usually severely incapacitated with dyspnea at minor
evels of exertion or at rest (New York Heart Association
NYHA] functional class III or class IV). Although the
ean preoperative PVR in CTEPH patients is 800 to 1,000
ynes·s·cm5, young patients with exertional dyspnea, al-
ost normal PVR at rest, and a significant increase at
xertion may also be accepted for surgery, as earlier opera-
ion could have the potential to prevent a secondary vascu-
opathy in the unobstructed pulmonary vascular bed.
The surgical accessibility of the thromboembolic lesions
s heavily dependent on the experience of the surgical team.
ith growing experience, endarterectomy of subsegmental
A branches is possible. The operative risk is increased if a
igure 1. Angiography depicts stenoses, complete obstructions, partial
ecanalization, and intraluminal webs and bands as classical signs of chronic
hromboembolic pulmonary hypertension.ajor discrepancy exists between the degree of PAH and phe extent of angiographic PA obstructions based on sig-
ificant microvascular disease.
rinciples of operation. Although the operation histori-
ally has been described as pulmonary thromboendarterec-
omy (PTE), it is better termed PEA (11). Fewer than
,000 PEA operations have been performed worldwide,
lthough it is a potentially curative treatment option for very
ick patients with CTEPH. The surgical techniques and
volving modifications have been well described by the San
iego group (14,15). With rare exceptions, thromboem-
olic pulmonary hypertension is a bilateral disease, and
herefore PEA is a bilateral procedure. The operation is not
n embolectomy but a true endarterectomy removing the
rganized and incorporated fibrous obstructive tissue from
he PAs. Because visibility in the distal PA branches is
ssential and bronchial artery collateral flow is significant in
TEPH, extracorporeal circulation and periods of circula-
ory arrest under deep hypothermia are essential for success-
ul endarterectomy.
Following a proximal intrapericardial PA incision, the
orrect endarterectomy plane is established and circumfer-
ntially followed down to the lobar segmental and some-
imes subsegmental branches of each lobe using special
uction dissectors. The endarterectomy procedure on one
ide is usually possible within one 20-min period of circu-
atory arrest followed by a period of reperfusion and another
eriod of circulatory arrest for the endarterectomy on the
ontralateral side. After closure of the PA incision, addi-
ional cardiac procedures can be performed during the
ewarming period, if necessary. As tricuspid valve compe-
ence usually returns after successful PEA, tricuspid valve
epair is not necessary.
Jamieson et al. (16) have proposed an intraoperative
lassification of CTEPH: type I (central thrombus present)
nd type II (thickened intima, fibrous webs and bands)
epresent the typical condition of surgical patients. Type III
cclusions in the segmental and subsegmental branches
equire adequate surgical experience with dissection within
he peripheral pulmonary arteries. Type IV disease repre-
ents secondary in situ thrombosis in patients with primary
ulmonary hypertension (PPH) and cannot be treated by
EA, whereas lung transplantation is an option for these
atients.
ostoperative management. In contrast to the majority of
ardiac surgical procedures, the postoperative course is deter-
ined primarily by the physiological changes of right heart
unction and pulmonary perfusion, pulmonary hemodynamics,
nd gas exchange (17). The postoperative management of
atients undergoing PEA can be challenging; in addition, the
sual complications associated with cardiac surgery are encoun-
ered. The most important complications are persistent PAH
ue to inadequate endarterectomy or significant secondary
asculopathy and reperfusion edema in the endarterectomized
arts of the lung (18). Postoperative care centers around
aintaining sufficient right ventricular function and organerfusion, adequate oxygenation and renal function, and in
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Surgical Therapy of PAH June 16, 2004:73S–80Sreventing early pulmonary artery reocclusion. Extensive cir-
ulatory monitoring, including continuous online measure-
ent of cardiac output, mixed venous oxygen saturation, and
rterial blood gases, has proved to be helpful.
Following nonaggressive pressure-controlled mechanical
entilation, early extubation on the first or second postop-
rative day is advocated even in cases with modest reperfu-
ion edema and hypoxia. In rare cases with severe reperfu-
ion edema, oxygenation can be improved by prone
igure 2. Postoperative and long-term follow-up hemodynamic changes
ainz, Germany, n  50). CI  cardiac index; mPAP  mean pulmonaositioning, continuous nitric oxide inhalation, or extracor soreal membrane oxygenation. By means of cautious fluid
nd albumin infusion, the doses of vasoactive drugs admin-
stered via left atrial catheter can be limited to a low dose
evel. Reocclusion prophylaxis is started within 4 to 8 h
ollowing surgery using intravenous heparin infusion fol-
owed by continuous anticoagulation with warfarin between
ays 8 and 14.
utcome. Recently, Fedullo et al. (18) have reviewed the
orld literature on thromboembolic pulmonary hyperten-
pulmonary endarterectomy (data from Johannes Gutenberg University,
ery pressure; PVR  pulmonary vascular resistance.after
ry artion and endarterectomy and found mortality rates between
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June 16, 2004:73S–80S Surgical Therapy of PAH% and 24%. As there is a distinct learning curve for the
reoperative evaluation, the operation, and the postopera-
ive care, mortality rates are lower in centers with a large
olume of procedures.
Although there has not been a controlled study, and such
n investigation probably will never be performed, the
utcomes of PTE with regard to functional status, quality of
ife, hemodynamics, right ventricular function, and gas
xchange are very favorable. Most patients are in NYHA
unctional class III or IV before the operation and return to
lass I or II with a good exercise capacity after surgery
19,20).
In several studies, significant and persistent decreases of
A pressures and PVR after PTE surgery are reported (19)
Fig. 2). Cardiac output is increased and oxygenation can be
ormalized. Right heart function assessed by echocardiog-
aphy or MRI is significantly and persistently improved
ostoperatively (Fig. 3). Tricuspid valve regurgitation is also
ignificantly improved within a few days after surgery; in
ost patients, tricuspid competence returns to normal.
Long-term survival after endarterectomy with a five-year
urvival rate of 75% to 80% is very favorable compared to
edical treatment or lung transplantation. Therefore, lung
ransplantation is inappropriate for most patients with this
igure 3. Cardiac magnetic resonance imaging before (A) and two weeks
fter pulmonary endarterectomy (B): Right heart dimensions are signifi-
antly decreased, and the left ventricle shows improved filling.ondition. mUNG AND HEART-LUNG TRANSPLANTATION
ith the advent of effective drug treatments in the last
ecade, lung transplantation has become the final option in
he management of PAH; at the same time, selection of
ecipients and timing of the procedure have become more
omplex.
Whereas prostaglandins and endothelin receptor antago-
ists can alter the clinical features and course of PPH in
any patients, their impact on the underlying pathobiology
s uncertain, and they are not curative remedies. The
ajority of patients already have moderate to severe PAH
hen the diagnosis is made, and all patients do not respond
o treatment. Less than 10% of patients with idiopathic
AH have a significant response to a calcium channel
ntagonist. Moreover, in two recent series approximately
5% of patients with PPH failed to improve with epopro-
tenol treatment, and those who remained in NYHA
unctional class III and IV with epoprostenol treatment had
poor prognosis, with three-year survival rates in the range
f 30% to 60% (21,22).
Finally, even among responders, the escalating dose of
poprostenol that is often needed to sustain its beneficial
ffects may eventually cause intolerable side effects. Thus,
ltimately transplantation will be the only alternative for
any patients with idiopathic PAH and other forms of
AH.
retransplantation assessment. The purpose of the pre-
ransplantation assessment is to identify patients whose
rognosis will be improved by transplantation and whose
ardiopulmonary status or other medical problems will not
nduly jeopardize the success of transplantation—that is, to
hoose the right patient and the right time for transplanta-
ion. The major specific goals of the evaluation for trans-
lantation are to confirm the diagnosis, to assess the severity
f the disease, and to optimize medical management. The
otential role of transplantation (prognosis of the disease vs.
hat of transplantation) has to be established, and suitable
andidates for transplantation have to be selected together
ith the ideal transplant procedure. The clinical status must
e reexamined periodically, and medical management and
ransplantation strategy adjusted accordingly.
Pathways, which are based on vasoreactivity and on
unctional impairment, have been standardized to optimize
he management paradigm, and transplantation should be
eserved until it will confer a survival advantage. However, a
ong waiting period for transplantation should be expected,
nd this delay has to be incorporated into the plan. Thus,
he pretransplantation evaluation and waiting list registra-
ion must anticipate the need for transplantation later, or
he opportunity for transplantation may be missed.
Consensus guidelines for selecting patients for transplan-
ation have been promulgated by the major societies (23),
nd most transplant centers use similar criteria. In addition
o a comprehensive assessment of the patient’s cardiopul-
onary status, any other medical problems should be fully
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Surgical Therapy of PAH June 16, 2004:73S–80Sharacterized to ascertain their potential influence on the
utcome of transplantation, and all health maintenance
esting that is recommended for the patient’s age and gender
hould be completed.
hoice of transplant operation. Choosing the transplant
peration is another facet of the preoperative evaluation.
oth heart-lung and lung transplantations have been per-
ormed for pulmonary vascular disease, but heart-lung
ransplantation should be reserved for patients who are not
andidates for lung transplantation alone. In general, most
orms of PAH except complex congenital heart disease do
ot require heart-lung transplantation unless there is a
ignificant cardiac problem other than cor pulmonale.
The threshold of unrecoverable right ventricular dysfunc-
ion is unknown, if such a boundary even exists. Severe right
entricular dysfunction has been reversible after isolated
ung transplantation. However, although afterload is imme-
iately reduced by lung transplantation, right ventricular
unction does not revert to normal right away, and hemo-
ynamic instability is a common problem in the early
ostoperative period.
Both single and bilateral lung transplantations have been
erformed for PPH and some other types of PAH (24–28),
nd these operations have been combined with repair of
ardiovascular anomalies for Eisenmenger syndrome
25,29). Single-lung transplantation creates a tenuous
entilation-perfusion imbalance, and any complication in
he allograft is associated with severe hypoxemia. Neverthe-
ess, recipient survival rates have been similar after single
nd bilateral transplantation for PAH, and if technically
easible, either of these operations is an acceptable choice for
ost cases of PAH. However, in patients with Eisenmenger
yndrome, the option of heart-lung transplantation should
e carefully considered. For some defects, especially ventric-
lar septal defect, the survival advantage of heart-lung
ransplantation was most prominent (29), and the option of
eart-lung transplantation should be strongly considered for
his subgroup.
iming. The pretransplantation assessment does not end
fter the initial evaluation and waiting list registration. The
aiting time for transplantation depends on the organ
llocation system, and allocation systems vary significantly
able 1. Recipient Survival After Lung and Heart Lung Transpla
Time
Surviva
PPH
LT
(691)
HLT
(302)
months 72% 72%
yr 64% 66%
yrs 54% 50%
yrs 44% 41%
0 yrs 21% 22%
ata from the Registry of the International Society for Heart and Lung Transplant
CHD  congenital heart disease; ES  Eisenmenger syndrome; HLT  heart lun countries around the world. Regardless of the allocation qystem, however, there is usually a long duration before
ransplantation, and during the waiting period both medical
anagement and transplantation strategy must be modified
n response to changes in clinical circumstances. Patients
ith PPH who are treated with epoprostenol should have a
ollow-up right heart catheterization. Those who have not
esponded to epoprostenol at their initial reassessment have
guarded prognosis (21,22) and they should proceed toward
ransplantation unless a contraindication intervenes.
Prognostic indexes that can be derived from repeatable,
oninvasive tests are needed to supplement clinical judg-
ent about the timing of transplantation after the patient is
n the waiting list. As medical therapy has improved, it has
een extended to its limit in many patients before trans-
lantation. However, if refractory right heart failure devel-
ps on maximal drug treatment, little can be done to restore
ardiopulmonary status, and secondary effects on other
rgans, especially the liver and kidney, become problematic.
n this scenario potential recipients can be transformed into
igh-risk or unacceptable candidates for transplantation,
nd the opportunity for transplantation can be lost.
Serial noninvasive tests may be helpful in the decision
bout timing. The results of the 6-min walk testing and
ardiopulmonary exercise testing have had prognostic im-
lications in a few studies (30,31) and the predictive value of
hese tests deserves further study. Six-minute-walk distance
orrelated well with peak oxygen uptake in one study of
PH patients, and a 6-min walk distance 332 m por-
ended a poor prognosis with a one-year mortality rate of
pproximately 40% (30). In a study of cardiopulmonary
xercise testing in patients with PPH, both peak oxygen
ptake and peak systolic blood pressure were prognostically
mportant. A peak oxygen uptake 10.4 ml/kg/min and a
eak systolic blood pressure 120 mm Hg were associated
ith one-year mortality rates of approximately 50% and
0%, respectively, and among patients with both of these
isk factors, only 23% survived for one year (31). Thus,
ransplantation would offer a survival benefit to patients
ith any of these risk factors, and this threshold might be
seful in foreseeing the favorable time for transplantation.
urvival. The outcome of lung transplantation can be
auged by several end points: survival, physiologic function,
ion (1990–2001)
iagnosis and Type of Transplant
ES Other CHD
6)
HLT
(376)
LT
(22)
HLT
(155)
% 76% 79% 59%
% 71% 68% 45%
% 57% 36% 32%
% 50% 36% 28%
% 39% 36% 7%
nsplantation; LT  lung transplantation; PPH  primary pulmonary hypertension.ntat
l by D
LT
(19
69
58
45
39
29
ation.uality of life, and cost-effectiveness. Actuarial survival is
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June 16, 2004:73S–80S Surgical Therapy of PAHell known from the U.S. Scientific Registry (32), the
nternational Society for Heart and Lung Transplantation
ISHLT) registry (33), and reports from individual centers
26,27,34,35). Survival rates from the ISHLT registry are
resented for PPH, Eisenmenger syndrome, and other
orms of congenital heart disease in Table 1.
Recipients with PPH and Eisenmenger syndrome have
ad the highest perioperative mortality and the lowest
hree-month survival rates among the major diagnostic
ategories of lung transplant recipients in both the U.S.
cientific and the ISHLT registries (32,33). This difference
s explained by the complexity of the surgery in severe
ulmonary hypertension. Cardiopulmonary bypass is re-
uired routinely for the operation in cases of PPH or
isenmenger syndrome, whereas it is rarely needed for other
iagnoses. This increases the risk of hemorrhagic compli-
ations and contributes to early graft dysfunction. Further-
ore, right ventricular function does not recover immedi-
tely, and hemodynamic instability is common in the first
ew days following transplantation.
In the ISHLT registry, both PPH and Eisenmenger
yndrome/congenital heart disease have been associated
ith a significantly higher risk of death in the first year after
ung transplantation than with other diagnoses (33). This
ncreased mortality has been concentrated in the perioper-
tive period; thereafter, the attrition rate for recipients with
PH and Eisenmenger syndrome has paralleled the rates for
ecipients with other diagnoses because the subsequent
omplications are not strongly influenced by the pretrans-
lantation diagnosis.
The best transplantation operation of PPH has been
ebated. No clearly significant difference in survival has
een apparent among the procedures (single lung transplan-
ation, bilateral lung transplantation, and heart-lung trans-
lantation) in the ISHLT registry and in some case series
27,33), but some centers have reported a different experi-
nce (35–37). In general, lung transplantation for PPH
hould be performed in specialized centers only, those
amiliar with the unique problems of this particular proce-
ure and the complexity of the patients.
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ersity Hospital of Vienna, Department of Cardio-Thoracic Surgery,
aehringer Guertel 18-20, 1090 Vienna, Austria. E-mail:
alter.klepetko@meduniwien.ac.at.
EFERENCES
1. Rich S, Lam W. Atrial septostomy as palliative therapy for refractory
primary pulmonary hypertension. Am J Cardiol 1983;51:1560–1.
2. Kerstein D, Levy PS, Hsu DT, et al. Blade balloon atrial septostomy
in patients with severe primary pulmonary hypertension. Circulation
1995;91:2028–35.
3. Rothman A, Slansky MS, Lucas VW, et al. Atrial septostomy as a
bridge to lung transplantation in patients with severe pulmonary
hypertension. Am J Cardiol 1999;84:682–6.
4. Sandoval J, Gaspar J, Pulido T, et al. Graded balloon dilation atrial
septostomy in severe primary pulmonary hypertension. A therapeuticalternative for patients non-responsive to vasodilator treatment. J Am
Coll Cardiol 1998;32:297–304.
5. Sandoval J, Rothman A, Pulido T. Atrial septostomy for pulmonary
hypertension. Clin Chest Med 2001;22:547–60.
6. Rich S, Dodin E, McLaughlin VV. Usefulness of atrial septostomy as
a treatment for primary pulmonary hypertension and guidelines for its
application. Am J Cardiol 1997;80:369–71.
7. Moscucci M, Dairywala IT, Chetcuti S, et al. Balloon atrial septos-
tomy in end-stage pulmonary hypertension guided a novel intracardiac
echocardiographic transducer. Catheter Cardiovasc Interv 2001;52:
530–4.
8. Allcock RJ, O’Sullivan JJ, Corris PA. Palliation of systemic sclerosis-
associated pulmonary hypertension by atrial septostomy. Arthritis
Rheum 2001;44:1660–2.
9. Pepke-Zaba J, McNeil K, Satchithanada DK, et al. Atrial septostomy
as a successful procedure improving symptoms and right heart failure
in patients with severe pulmonary hypertension. Thorax 2000;55 Suppl
3:A48.
0. Sandoval J, Barst RJ, Rich S, Rothman A. Atrial septostomy for
pulmonary hypertension. In: Rich, S, editor. Primary Pulmonary
Hypertension: Executive Summary From the World Symposium on
PPH 1998. Available at: http://www. Who.int/ncd/cvd/pph.html.
1. Jamieson SW, Kapelanski DP, Sakakibara N, et al. Pulmonary
thromboendarterectomy. Experience and results in 1,500 cases. Ann
Thorac Surg 2003;76:1457–64.
2. Moser KM, Auger WR, Fedullo PF. Chronic major-vessel thrombo-
embolic pulmonary hypertension. Circulation 1990;81:1735–43.
3. Lewczuk J, Piszko P, Jagas J, et al. Prognostic factors in medically
treated patients with chronic pulmonary embolism. Chest 2001;119:
818–23.
4. Jamieson SW, Auger WR, Fedullo PF, et al. Experience and results
with 150 pulmonary thromboendarterectomy operations over a 29-
month period. J Thorac Cardiovasc Surg 1993;106:116–27.
5. Daily PO, Dembitsky WP, Iversen S. Technique of pulmonary
thromboendarterectomy for chronic pulmonary embolism. J Card Surg
1989;4:10–24.
6. Thistlethwaite PA, Mo M, Madani MM, et al. Operative classification
of thromboembolic disease determines outcome after pulmonary end-
arterectomy. J Thorac Cardiovasc Surg 2002;124:1203–11.
7. Fedullo PF, Auger WR, Dembitsky WP. Postoperative management
of the patient undergoing pulmonary thromboendarterectomy. Semin
Thorac Cardiovasc Surg 1999;11:172–8.
8. Fedullo PF, Auger WR, Kerr KM, Rubin LJ. Chronic thromboem-
bolic pulmonary hypertension. N Engl J Med 2001;345:1465–72.
9. Mayer E, Dahm M, Hake U, et al. Mid-term results of pulmonary
thromboendarterectomy for chronic thromboembolic pulmonary hy-
pertension. Ann Thorac Surg 1996;61:1788–92.
0. Archibald CJ, Auger WR, Fedullo PF, et al. Long-term outcome after
pulmonary thromboendarterectomy. Am J Respir Crit Care Med
1999;160:523–8.
1. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmo-
nary hypertension. The impact of epoprostenol therapy. Circulation
2002;106:1477–82.
2. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous
epoprostenol infusion in primary pulmonary hypertension. Prognostic
factors and survival. J Am Coll Cardiol 2002;40:780–8.
3. International guidelines for the selection of lung transplant candidates.
Joint statement of the American Society for Transplant Physicians
(ASTP)/American Thoracic Society (ATS)/European Respiratory
Society (ERS)/International Society for Heart and Lung Transplan-
tation (ISHLT). Am J Respir Crit Care Med 1998;158:335–9.
4. Pasque MK, Trulock EP, Kaiser LR, Cooper JD. Single-lung trans-
plantation for pulmonary hypertension: three-month hemodynamic
follow-up. Circulation 1991;84:2275–9.
5. Bando K, Armitage JM, Paradis IL, et al. Indications for and results of
single, bilateral and heart–lung transplantation for pulmonary hyper-
tension. J Thorac Cardiovasc Surg 1994;108:1056–65.
6. Pasque MK, Trulock EP, Cooper JD, et al. Single lung transplantation
for pulmonary hypertension: single institution experience in 34 pa-
tients. Circulation 1995;92:2252–8.
7. Gammie JS, Keenan RJ, Pham SM, et al. Single versus double lung
transplantation for pulmonary hypertension. J Thorac Cardiovasc Surg
1998;115:397–403.
22
3
3
3
3
3
3
3
3
80S Klepetko et al. JACC Vol. 43, No. 12 Suppl S
Surgical Therapy of PAH June 16, 2004:73S–80S8. Mendeloff EN, Meyers BF, Sundt TM, et al. Lung transplantation for
pulmonary vascular disease. Ann Thorac Surg 2002;73:209–19.
9. Waddell TK, Bennett L, Kennedy R, Todd TRJ, Keshavjee SH.
Heart–lung or lung transplantation for Eisenmenger syndrome.
J Heart Lung Transplant 2002;21:731–7.
0. Miyamoto S, Nagaya N, Satoh T, et al. Clinical correlates and prognostic
significance of six-minute walk test in patients with primary pulmonary
hypertension. Am J Respir Crit Care Med 2000;161:487–92.
1. Wensel R, Opitz CF, Anker SD, et al. Assessment of survival in
patients with primary pulmonary hypertension. Importance of cardio-
pulmonary exercise testing. Circulation 2002;106:319–24.
2. 2001 Annual Report of the U.S. Organ Procurment and Transplan-
tation Network and the Scientific Registry of Transplant Recipients:
Transplant Data 1991–2000: Department of Health and Human
Services, Health Resources and Services Administration, Office of
Special Programs, Division of Transplantation, Rockville, MD;United Network for Organ Sharing, Richmond, VA; University Renal
Research and Education Association, Ann Arbor, MI.
3. Hertz MI, Taylor DO, Trulock EP, et al. The registry of the
International Society for Heart and Lung Transplantation: Nineteenth
Official Report 2002. J Heart Lung Transplant 2002;21:950–70.
4. Whyte RI, Robbins RC, Atlinger J, et al. Heart–lung transplantation for
primary pulmonary hypertension. Ann Thorac Surg 1999;67:937–42.
5. Franke U, Wiebe K, Harringer W, et al. Ten years’ experience with
lung and heart-lung transplantation in primary and secondary pulmo-
nary hypertension. Eur J Cardiothorac Surg 2000;18:447–52.
6. Conte JV, Borja MJ, Patgel CB, Yang SC, Jhaveri RM, Orens JB.
Lung transplantation for primary and secondary pulmonary hyperten-
sion. Ann Thorac Surg 2001;72:1673–80.
7. Pereszlenyi A, Lang G, Steltzer H, et al. Bilateral lung transplantation
with intra- and postoperatively prolonged ECMO support in patients
with pulmonary hypertension. Eur J Cardiothorac Surg 2002;21:858–
63.
